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Abstract
Fragile X syndrome (FXS) is the most common form of inherited intellectual disability and the leading known genetic cause
of autism. Fragile X mental retardation protein (FMRP), which is absent or expressed at substantially reduced levels in FXS,
binds to and controls the postsynaptic translation of amyloid b-protein precursor (AbPP) mRNA. Cleavage of AbPP can
produce b-amyloid (Ab), a 39–43 amino acid peptide mis-expressed in Alzheimer’s disease (AD) and Down syndrome (DS).
Ab is over-expressed in the brain of Fmr1
KO mice, suggesting a pathogenic role in FXS. To determine if genetic reduction of
AbPP/Ab rescues characteristic FXS phenotypes, we assessed audiogenic seizures (AGS), anxiety, the ratio of mature versus
immature dendritic spines and metabotropic glutamate receptor (mGluR)-mediated long-term depression (LTD) in Fmr1
KO
mice after removal of one App allele. All of these phenotypes were partially or completely reverted to normal. Plasma Ab1–42
was significantly reduced in full-mutation FXS males compared to age-matched controls while cortical and hippocampal
levels were somewhat increased, suggesting that Ab is sequestered in the brain. Evolving therapies directed at reducing Ab
in AD may be applicable to FXS and Ab may serve as a plasma-based biomarker to facilitate disease diagnosis or assess
therapeutic efficacy.
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Introduction
FXS is an X chromosome-linked disorder characterized by
highly variable intellectual disability, autistic-like behavior and
seizures [1]. In the vast majority of cases, FXS results from a .200
trinucleotide (CGG) repeat expansion in the 59-UTR of the FMR1
gene [2] leading to transcriptional silencing and loss or reduction
of expression of FMRP [3]. FMRP is a multi-functional mRNA
binding protein involved in the dendritic transport, localization
and translational regulation of several hundred mRNA ligands [4–
9]. In the absence of FMRP, dendritic spine morphology and
function are abnormal [10]. Thus, FXS is likely caused by the
inappropriate, post-synaptic expression of one or more FMRP
mRNA targets. We have previously demonstrated that post-
synaptic translation of App mRNA is regulated by FMRP through
a mGluR5-dependent pathway. In the absence of FMRP, excess
AbPP and its catabolites Ab1–40 and Ab1–42, accumulate in the
brains of middle-aged Fmr1
KO mice [11].
There is very limited data regarding the roles of AbPP mRNA,
protein and catabolites in persons with FXS. One group showed
elevated App mRNA in the cerebral cortex, hippocampus and
cerebellar cortex in Fmr1
KO mice [12], but we have not observed
differences in cortical synaptoneurosomes [11]. Increased Ab levels
would predict an increased incidence of AD pathology in aged FXS
individuals, which has not been observed in neuropathological
analyses of a very small number of specimens [13–15]. Likewise,
there are no reports of an increased incidence of AD inFXS, but it is
difficult to assess age-related dementia in the mentally retarded and
very few elderly individuals with FXS have been studied in
significant numbers. Recent data suggests that AbPP or its
proteolytic derivatives may be aberrantly expressed in children with
severe autism [16,17], which is extremely prevalent in FXS (67% of
males and 23% of females) [18] and DS (7%) [19]. Thus, the
increased production or altered processing of AbPP may contribute
to the intellectual disabilities observed in all of these disorders.
Herein, we demonstrate rescue of several Fmr1
KO phenotypes in
model mice by genetic modulation of AbPP/Ab levels. Treatment
of primary neurons with Ab1–42 rapidly triggered extracellular-
regulated kinase (ERK) signaling and altered the translation of
multiple FMRP target mRNAs including App. Conversely, anti-Ab
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Ab modulates its own production through a positive feedback
loop. Finally, we show that plasma Ab1–42 is significantly reduced
while cerebral Ab1–42 is likely increased in full-mutation FXS
males. These data suggest evolving therapies directed at reducing
Ab in AD may be applicable to FXS and plasma Ab1–42 may be a
biomarker for disease severity and drug efficacy in FXS.
Results
Genetic Modulation of AbPP Levels in Fmr1
KO Mice
Reduces AGS
Compared to WT, Fmr1
KO mice exhibit AGS [20], altered
anxiety [21–23] and dendritic spine dysmorphogenesis [24–26],
features shared with patients with FXS [1,27,28]. In order to
establish if AbPP or Ab directly contributed to FXS pathogenesis,
we modulated AbPP and Ab expression in Fmr1
KO mice. Thus, we
generated Fmr1
KO/App
HET and Fmr1
KO/App
KO mice all in a pure
C57BL/6 background to evaluate the effects of genetic modula-
tion of AbPP and Ab expression. Western blot analyses confirmed
that AbPP levels were reduced by 50% in Fmr1
KO/App
HET mice
(Figure 1A). At 21 days of age, animals were evaluated for AGS.
Wild running (WR) and seizures decreased 32% and 54%,
respectively, in Fmr1
KO/App
HET mice (Figure 1B). These data
suggest that seizures are enhanced when AbPP is absent or over-
expressed and that AbPP or one of its metabolites significantly
contributes to the AGS phenotype seen in Fmr1
KO mice.
Pharmacological antagonists directed at or genetic reduction of
mGluR5 correct many Fmr1
KO phenotypes [22,26,29–31]. We
compared the efficacy of mGluR5 antagonists with genetic
manipulation of AbPP/Ab in reducing AGS in Fmr1
KO mice. A
30 min pretreatment with 2-methyl-6-(phenylethynyl)pyridine
hydrochloride (MPEP) delivered by I.P. injection reduced WR,
AGS and deaths by 82%, 75% and 100%, respectively (Figure 1B).
An alternative mGluR5 antagonist, fenobam, reduced WR, AGS
and deaths to 0% (data not shown).
Fmr1
KO/App
HET Mice Lack FXS Behavioral, Dendritic Spine
and mGluR-LTD Phenotypes
Hyperactivity, social anxiety and autistic-like behaviors are
characteristic features of FXS [1]. We first assessed marble
burying in these mice as a measure of repetitive behavior [32].
Fmr1
KO male mice buried significantly fewer marbles than WT
(p=0.04) (Figure 2A), which was rescued in male Fmr1
KO/App
HET
mice (statistically different compared to Fmr1
KO, p=0.03; not
different from WT, p=0.95). Thus, repetitive digging is a normal
mouse behavior that can be rescued in Fmr1
KO male mice by
genetically reducing AbPP/Ab levels.
Next, we assessed hyperactivity (Figure 2B) and anxiety
(Figure 2C, D) in the open field test. Fmr1
KO exhibit increased
center time (reflecting a loss of anxiety) but equivalent locomotion
in the open field compared with WT mice [21,22]. App
HET and
App
KO mice exhibited significantly more anxiety/thigmotaxis than
WT mice (Figure 2C). The increased thigmotaxis in the App
HET is
partially due to decreased locomotion compared with WT mice
(Figure 2B); however, total distance traveled was equivalent
between App
KO and App
HET indicating that decreased AbPP /Ab
levels correlate with increased anxiety. Fmr1
KO/App
HET mice
exhibited equivalent center time as WT mice and significantly
less than Fmr1
KO mice indicating that thigmotaxis was rescued.
Total distance traveled in the open field was not statistically
different between Fmr1
KO/App
HET, WT and/or Fmr1
KO mice
indicating equivalent locomotion.
Pathological examination of brains from FXS patients has
shown an increased density of long and tortuous dendritic spines
suggesting a delay in spine maturation [15,33]. We assessed
dendritic spine length in primary cultured neurons and found a
statistically significant 1.6-fold increase in protrusion length in the
Fmr1
KO cells compared to WT (Figure 3A, B) in agreement with the
literature [24–26]. A 4 hr treatment with mGluR5 antagonists
(MPEP or fenobam) rescued the spine/filopodia ratio in Fmr1
KO
mice to WT levels [26]. Likewise, we observed that both dendritic
spine length and the percentage of filopodia in primary cultured
Fmr1
KO neurons were reverted to WT levels within 15 min of
MPEP treatment (Figure 3B). Average protrusion length was
reduced by 11% in the Fmr1
KO/App
HET cells (statistically significant
p,0.03 compared to Fmr1
KO), and the percentage of filopodia
(immature spines) versus mature spines was completely reverted to
Figure 1. AGS are rescued by genetic manipulation of App or
mGluR5 blockade. (A) western blot analyses of AbPP levels in Fmr1
KO,
WT, App
HET and Fmr1
KO/App
HET mice (n=3 male mice per strain, 1
month old). Statistics: one-way ANOVA p,0.0001, F=53.95. Stars (w)
denote statistically different levels by Student T-test analyses and by
Bonferroni’s multiple comparison test (p,0.05). Error bars represent
SEM. (B) Assessment of WR, AGS and death rates in Fmr1
KO mice (age
P21, n=58)) after genetic manipulation of AbPP levels (n=23) or
treatment with MPEP (n=14). Stars (w) denote rates that are statistically
different from untreated mice (p,0.5) by Fisher exact tests.
doi:10.1371/journal.pone.0026549.g001
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KO neurons
has been reported to rescue the percentage of mature spines to
WT levels albeit without a significant change in dendritic
protrusion length [24].
Fmr1
KO mice exhibit enhanced hippocampal mGluR-long term
depression (LTD), which requires rapid protein synthesis [34,35].
We assessed hippocampal mGluR-LTD by field recordings in 3-
month-old male WT, Fmr1
KO, App
HET and Fmr1
KO/App
HET mice.
mGluR-dependent synaptic depression was enhanced in the CA1
in Fmr1
KO slices, equivalent in WT and App
HET and reduced in
Fmr1
KO/App
HET (statistically significant p,0.0002 comparing
Fmr1
KO/App
HET and Fmr1
KO) (Figure 4). The time course of CA1
fEPSP slopes after DHPG treatment reveals a significant difference
between Fmr1
KO animals relative to wild type, App
HET and
Fmr1
KO/App
HET mice. Input/output relationships and paired-pulse
facilitation (ppf) were analyzed to assess the basal synaptic
properties of the different groups (Figure S1), and did not show
significant changes between experimental groups indicating
unaltered synaptic transmission in the Fmr1
KO hippocampus.
Ab1–42 Alters Dendritic Expression of FMRP Targets
To begin to understand how excessive production and/or
processing of AbPP mediates cell signaling events, we examined
dendritic expression of select FMRP targets after treating WT
primary neurons with soluble Ab1–42. There was a .2-fold
increase in the expression of AbPP, no change in Arc, 40%
increase in Map1B, 85% increase in RhoB and 50% decrease in
PSD95 (Figure 5A). The Ab1–42-mediated increase in dendritic
AbPP could be blocked with MPEP or anisomycin indicating that
it was mGluR5- and translation-dependent (Figure 5B). Converse-
ly, reduction of Ab in the cell culture media by treatment with
anti-Ab antibody through a transwell reduced dendritic AbPP
expression by 31% (Figure 5C). We utilized transwells to avoid
direct contact between the antibody and the cells as direct
application of anti-Ab to the culture media dramatically increased
AbPP expression presumably due to cell signaling events initiated
by anti-Ab binding to cell surface receptors (data not shown).
MPEP and Ab1–42 altered phosphorylated levels of ERK (Figure
S2), suggesting that the mitogen activated protein kinase pathway
is as an intermediate in Ab-mediated AbPP translation.
Ab1–42 Levels are Abnormal in Humans with FXS
We are unaware of any published data evaluating AbPP or its
products in the blood of adult FXS patients. We found that plasma
AbPP/AbPPa and Ab1–40 levels were comparable in adult FXS
patients and controls (Figure 6A, B). These results are distinct from
those previously observed in children [16] and suggest that AbPP
expression and processing decrease with age. Indeed, AbPPa levels
Figure 2. Rescue of behavioral phenotypes in adult Fmr1
KO mice by genetic manipulation of App. (A) male App
KO (n=8), App
HET (n=14),
WT (n=7), Fmr-1
KO (n=8), Fmr1
KO/App
HET (n=10) and Fmr1
KO/App
KO (n=4) mice (8–10 weeks old) were assessed for marble burying activity. Statistics:
one-way ANOVA p,0.022, F=2.95. (B, C and D) Mice were assessed for anxiety levels and locomotion in the open field. Both genders were included
as the males and females exhibited equivalent locomotion and anxiety in the open field [App
KO (n=11), App
HET(n=23), WT (n=15), Fmr1
KO (n=14),
Fmr-1
KO/App
HET (n=18) and Fmr1
KO/App
KO (n=7)]. (B) Total distance (cm) traveled is plotted against mouse strain. Statistics: one-way ANOVA
p,0.0005, F=4.59. (C) Time (sec) spent in the center of the arena is plotted versus mouse strain. Statistics: one-way ANOVA p,0.0001, F=5.98. (D)
Distance (cm) traveled in the center of the arena is plotted versus mouse strain. Statistics: one-way ANOVA p,0.0001, F=9.17. Stars (w) denote
statistically different levels by Student T-test analyses (p,0.5). All error bars represent SEM.
doi:10.1371/journal.pone.0026549.g002
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older [16]. While plasma Ab1–40 levels were unchanged between
FXS and controls, Ab1–42 was significantly lower in the FXS group
(2.1-fold decrease, p,0.004) (Figure 6B). As seen in other
amyloidogenic diseases, the Ab1–42/Ab1–40 ratio (1.4:1) in blood
plasma was substantially reduced compared to controls (3.4:1)
suggesting decreased clearance from the brain. There was no
statistically significant increases in cell-associated AbPP, secreted
AbPPa nor APP695/751/770 mRNA in peripheral blood mononu-
clear cells (PBMC) samples from FXS and control donors
(Figure 6A and data not shown).
We next assessed AbPP/AbPPa,A b1–40 and Ab1–42 in
hippocampal and neocortical control and FXS autopsy brain
tissue. The data represents analyses of four FXS and three control
brains. There is a strong trend toward increased soluble Ab1–40 in
lysates of FXS brain samples (Figure 6D) while AbPP/AbPPa
levels are reciprocally decreased (Figure 6C) in both the neocortex
and hippocampus. Despite the small sample size due to the
unavailability of tissue, the 1.7-fold decrease in AbPP/AbPPa in
neocortex approaches statistical significance. These data suggest
that the brain may act as a sink for Ab and that lower blood
plasma levels may indicate increased brain deposition. These
results are similar to those in Fmr1
KO mice, which exhibited
elevated Ab in the brain [11]. Murine Ab levels in blood plasma
were below the ELISA detection limit and could not be
determined.
These data strongly support the hypothesis that modest over-
expression of AbPP and/or Ab, in the context of the Fmr1
KO,i s
necessary for many of the pathological phenotypes including AGS,
anxiety, dendritic dysmorphogenesis and mGluR-LTD observed
in the mice and that these effects are likely mediated by mGluR5
signaling. Furthermore, these data suggest a positive feedback loop
whereby extracellular Ab stimulates dendritic translation of AbPP
Figure 3. Dendritic spine morphology is partially rescued in
Fmr1
KO/App
HET or MPEP treated Fmr1
KO mice. (A) Representative
fluorescent images of primary cultured neurons prepared from WT
(upper left), Fmr1
KO (upper right and lower left) and Fmr1
KO/App
HET
(lower right) embryos stained with DiI and visualized by fluorescent
microscopy (1006 objective). The arrows denote dendritic spines. (B)
The lengths of dendritic protrusions were quantitated with Stereo-
Investigator software and plotted against mouse strain/treatment. The
percentage of filopodia versus spines for each condition is given below
the histogram. Statistics: one-way ANOVA comparison of the three
genotypes (untreated) p,0.0001, F=27.18. All genotypes are statisti-
cally different from each other by Student T-Test and Bonferroni’s
multiple comparison tests. Two-way ANOVA comparison of WT versus
Fmr1
KO 6 MPEP: p,0.0001, F=12.89 (interaction), F=35.01 (genotype)
and F=27.62 (MPEP). The untreated and 15 min MPEP treated WT
spines are statistically different from the corresponding Fmr1
KO spines
by the Bonferroni multiple comparison test (p,0.5). Stars (w) denote
statistically different spine lengths by Student T-test analyses (p,0.5).
Error bars indicate SEM [Fmr1
KO: untreated (n=746 spines), 15 min
MPEP (n=263), 1 hr MPEP (n=300), 4 hr MPEP (n=293); WT: untreated
(n=994), 15 min MPEP (n=535), 1 hr MPEP (n=373), 4 hr MPEP
(n=1221); Fmr1
KO/App
HET (n=2469)].
doi:10.1371/journal.pone.0026549.g003
Figure 4. Rescue of mGluR-dependent synaptic depression in
the CA1 in Fmr1
KO/App
HET mice. (Top) Representative fEPSP taken
before the addition of DHPG (solid lines) and at the end of the
recordings (dotted lines). (Bottom) Time course of CA1 fEPSP slope after
incubation with DHPG (50 mM, 10 min) in hippocampal slices from WT
(black circles) (n=20), Fmr1
KO (white circles) (n=13), App
HET (black
triangles) (n=15) and Fmr1
KO/App
HET (white triangles) (n=10) male
mice (3 months old). WT, App
HET and Fmr1
KO/App
HET were all statistically
different from Fmr1
KO by two-way ANOVA/Bonferroni multiple com-
parison tests. WT versus App
HET, p=0.92; WT versus Fmr1
KO,p ,0.006;
WT versus Fmr1
KO/App
HET,p ,0.02; App
HET versus Fmr1
KO/App
HET,
p,0.04; App
HET versus Fmr1
KO, p=0.02; Fmr1
KO versus Fmr1
KO/App
HET,
p,0.0002. Error bars indicate SEM.
doi:10.1371/journal.pone.0026549.g004
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amyloidogenic processing and the generation of additional Ab.
Discussion
FXS is the most common form of inherited mental retardation
and autism. It is caused by the loss of FMRP, an mRNA binding
protein, which localizes to dendrites and regulates protein
synthesis. Considerable effort has focused on characterizing the
FMRP mRNA ligands and signaling pathways, particularly
mGluR5 [36], that contribute to FXS phenotypes. We have
demonstrated that App mRNA is an FMRP mRNA ligand whose
translation is regulated through mGluR5 [11].
AbPP plays a critical physiological role in synapse formation
and maintenance [37,38] with expression increasing during
neuronal differentiation, maximal during synaptogenesis and
decline when mature connections are completed [39–42].
Maximal AbPP expression coincides with the critical period of
sensory development in rodents (postnatal weeks 2–6) [43]. FMRP
is also developmentally regulated in the neonatal brain where it
peaks at the end of the first postnatal week and declines thereafter
[44]. AbPP is processed by a-, b- and/or c-secretases to produce
soluble N-terminal domains of AbPP (sAbPPa and sAbPPb), Ab
and C-terminal fragments. Ab, which is over-expressed in AD and
DS [45], is strongly implicated in impaired synaptic function and
synapse loss observed early in the development of AD [46,47], and
we propose that their dysregulated production in FXS contributes
to disease pathology. From conception, DS individuals over-
express APP mRNA, AbPP and extracellular amyloid [48,49]. Like
FXS, DS patients show mental retardation, craniofacial abnor-
malities and dendritic dysmorphogenesis [1,50]. Thus, increased
AbPP and/or AbPP proteolytic products could provide a common
effector at the molecular level for the neuroanatomic and
behavioral phenotypes observed in all of these disorders [51].
Figure 5. Ab1–42 alters dendritic protein levels. (A) WT neuronal cells treated with vehicle, 20 or 100 nM Ab1–42 for 1 hr followed by fixation and
staining for AbPP, Arc/Arg, Map1B, RhoB and PSD95 and analyses by confocal fluorescent microscopy. (B) WT neuronal cells pre-treated with vehicle,
2.5 mM MPEP or 40 mM anisomycin for 15 min prior to treatment with 20 nM Ab1–42 for 1 hr and fixation and staining for AbPP. Statistics: one-way
ANOVA p,0.0001, F=7.04. All treatments are statistically different from the 20 nM Ab1–42 treatment by the Bonferroni multiple comparison test
(p,0.05). A minimum of 1793 particles were analyzed per treatment cohort. (C) WT neuronal cells treated with mouse IgG or anti-Ab antibody in
transwells for 3 days prior to fixation and staining for AbPP. Statistics: one-way ANOVA p,0.05, F=3.03. A minimum of 2,644 particles were analyzed
per treatment cohort. Stars (w) denote statistical differences by Student T-test analyses (p,0.5). Error bars indicate SEM.
doi:10.1371/journal.pone.0026549.g005
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Ab1–42/Ab1–40 ratio were significantly decreased in full-mutation
FXS males compared to control donors. A reduced Ab1–42/Ab1–40
ratio is an independent risk factor for AD irrespective of the total
Ab load [52–58]. Plasma Ab1–42 levels are increased in patients
with mild cognitive impairment, but drop to control levels by the
time of AD diagnosis [59]. In DS, elevated plasma Ab1–42 is
associated with earlier onset of AD [60] and the Ab1–42/Ab1–40
blood plasma ratio is lower than in controls [61]. Thus, our finding
of a reduced Ab1–42/Ab1–40 ratio in FXS patients compared to
control plasma is consistent with other amyloidogenic diseases.
The effectiveness of drug therapy in FXS is currently assessed
exclusively by behavioral testing. Perhaps most importantly, the
availability of a plasma biomarker for FXS may permit the
monitoring of drug therapy as well as predict disease progression.
Other studies have demonstrated reduced cAMP production in
platelets [62] and delayed early-phase phosphorylation of ERK in
lymphocytes [63] from FXS patients. Our data demonstrates that
Ab1–42 is significantly lower in FXS plasma than control subjects,
and in conjunction with two studies demonstrating elevated
sAbPPa in autistic children [16,17], suggests that both AbPP and
Ab are viable biomarkers for FXS. We did not observe increased
sAbPPa in adult FXS plasma suggesting that AbPP expression and
processing decrease with age consistent with prior studies [16].
Previously reported control plasma levels of Ab range from 130–
208 pg/mL for Ab1–40 and 15 pg/mL–85.7 ng/mL for Ab1–42
[53,58,64,65]. Thus, there is wide range of reported plasma Ab1–40
and Ab1–42 levels in the literature and our studies fall within that
range. A critical question remains regarding if these catabolites are
associated with disease severity or progression. There is a paucity of
human FXS brain tissue available for analyses. Our preliminary
studies indicate a trend for elevated Ab in FXS brain, which agrees
with data in Fmr1
KO mice [11].
FXS patients exhibit hyper-reactivity to visual, olfactory, tactile
and auditory stimulation [1,66–69]. This hypersensitivity pheno-
type is manifested as AGS in Fmr1
KO mice [20]. If Ab contributes
to AGS, then AD and DS mice would also be susceptible to
seizures. Consistent with this, Tg2576, FRAXAD and DS mice,
which all over-express hAbPP with the Swedish familial mutation
and/or mouse AbPP, exhibit AGS [70]. Fmr1
KO/App
HET male
mice exhibited a statistically significant decrease in AGS but not in
WR whereas MPEP significantly reduced WR in Fmr1
KO mice.
These data suggest that the reduction of AbPP/Ab in Fmr1
KO mice
is not particularly effective at reducing the induction of AGS, but
does retard progression to clonic-tonic seizures. Fmr1
KO mice also
exhibit enhanced mGluR-LTD [34], which is lost in Fmr1
KO/
Figure 6. AbPP/Ab are abnormal in blood and brain from FXS patients. (A) AbPPa levels in control (n=7) and FXS (n=10) plasma and PBMC
culture media (n=7 controls and 4 FXS) and AbPP in PBMC (n=7 controls and 5 FXS). For the plasma and PBMC culture media data, AbPPa is
expressed as ng/mL and for the PBMC lysate measurements, AbPP is expressed as ng/mL/mg lysate. (B) Ab1–40 and Ab1–42 levels in control (n=7) and
FXS (n=10) plasma. For Ab1–42,p ,0.004 as determined by Student T-Test analyses. (C) AbPP/AbPPa in control (n=3) and FXS (n=4) neocortex and
hippocampus. Controls were gender- and age-matched to FXS donors by the University of Maryland Brain Bank. All of the donors were Caucasian
males and their ages ranged from 21–85 years old. (D) Soluble Ab1–40 levels in control (n=3) and FXS (n=4) neocortex and hippocampus. White
bars=control samples and gray bars=FXS. Error bars represent SEM.
doi:10.1371/journal.pone.0026549.g006
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HET mice. The Fmr1
KO reduces mGluR-LTD in an App
HET
background, but enhances mGluR-LTD in an App
WT background.
The large difference in the maximal depression of synaptic
transmission between Fmr1
KO/App
HET and Fmr1
KO in opposite
directions from WT mice, which exhibit equivalent mGluR-LTD
as App
HET, suggests that FMRP and AbPP/Ab play important and
synergistic roles in modulating mGluR-LTD. Thus, the over-
expression of AbPP or an AbPP catabolite lowers seizure threshold
and enhances mGluR-LTD, and approaches to attain normal
synaptic levels of these proteins could prove therapeutic.
MPEP is a potent and highly selective noncompetitive
antagonist of mGluR5 [71,72] that reduces AGS, anxiety
phenotypes and dendritic spine protrusion morphology in Fmr1
KO
[22,26]. We have previously demonstrated that mGluR5 blockade
inhibits translation of AbPP in synaptoneurosomes [11] and herein
demonstrate reversion of several FXS phenotypes by genetic
manipulation to reduce AbPP/Ab. Minocycline, a second-
generation tetracycline compound, reverts several FXS pheno-
types [24], possibly by altered Ab fibril formation [73] or Ab-
induced neuronal death and glial activation [74]. In aggregate,
these data suggest that mGluR5 antagonists and minocycline
therapies converge on a similar signaling pathway resulting in
decreased Ab levels/activity as obligatory for the rescue of FXS
phenotypes.
How Ab mediates synaptic dysfunction remains unclear. Ab
promotes AD-like cytoskeletal abnormalities and can promote
intracellular accumulation of sAbPP in primary cultured neurons
[75]. Soluble oligomers of Ab increase LTD in WT hippocampal
slices and inhibit long-term potentiation [76–80]. A similar
enhancement of mGluR5-mediated LTD occurs in the hippo-
campus of Fmr1
KO mice [34], and MPEP prevents the block in
long-term potentiation [81]. Ab causes membrane depolarization
and calcium influx, activates mGluR1 [82] and functions as an
extracellular scaffold for mGluR5 [83]. In vitro,A b1–42 altered the
expression of important dendritic proteins regulated by FMRP
including AbPP, Map1B and PSD95 with known roles in
synaptogenesis and/or dendritic spine morphology [37,38,44,
84]. A previous report utilizing neuronal hybrid cells demonstrated
that Ab1–40 increases AbPP levels also supporting the existence of
an Ab-driven positive feedback loop [85]. Lower levels of PSD95
are observed in Tg2576 neurons, which constitutively overexpress
Ab and ADDLs [84]. In our hands, levels of the immediate-early
gene Arc were not changed during a 1 hr stimulation with low
molecular weight oligomers of Ab1–42; however, others have
observed that higher molecular weight Ab oligomers (10–100 kDa)
bind in a punctate pattern to the surface of neurons, colocalize
with PSD95 and upregulate Arc [47]. We can block the Ab-
induced increase in AbPP levels with either MPEP or anisomycin
suggesting that an mGluR5- and translation-dependent pathway is
involved. The varied expression of known FMRP targets in
response to Ab suggests that dendritic translation can be
modulated through FMRP-dependent and independent pathways.
Ab1–42 rapidly increases phosphorylated ERK levels suggesting
that ERK mediates downstream signaling.
In conclusion, our work demonstrates that AbPP translation is
regulated through an mGluR5/FMRP-mediated pathway. Exces-
sive signaling through mGluR5 in the absence of FMRP leads to
increased AbPP production and processing and we have observed
elevated AbPP and Ab levels in Fmr1
KO mice [11]. Genetic
reduction of AbPP levels in Fmr1
KO mice has reverted or partially
rescued FXS seizure, behavioral, dendritic spine and mGluR-
LTD phenotypes. Furthermore, treatment of primary neurons
with Ab1–42 increased while anti-Ab reduced dendritic AbPP
expression suggesting that an Ab-driven positive feedback loop
drives synthesis/processing of AbPP through a mGluR5 signaling
pathway. Our results have potential implications for the treatment
of FXS as plasma AbPP/Ab can be readily screened as biomarkers
to evaluate potential therapies including mGluR5 antagonists as
well as secretase inhibitors and anti-Ab, which are currently
undergoing testing for the treatment AD.
Materials and Methods
Ethics Statement
Adequate measures were taken to minimize pain or discomfort
to the mice, and all husbandry, seizure and euthanasia procedures
were performed in accordance with NIH and an approved
University of Wisconsin-Madison animal care protocol adminis-
tered through their Research Animal Resources Center (approval
#G00468). Males with FXS and age-matched controls were
recruited from the FXS Clinic at Rush University Medical Center
(RUMC) in Chicago, IL. The study was approved by the RUMC
Institutional Review Board and all donors or their legal guardians
signed the appropriate consent forms for study participation.
Mouse Husbandry
WT and Fmr1
KO mice (C57BL/6 background) were bred and
housed as previously described) [11]. Fmr1
KO females [86] were
crossed with App
KO males [87] (Jackson Laboratories #004133,
C57BL/6 background) to generate Fmr1
HET/App
HET females and
Fmr1
KO/App
HET males that were crossed to generate Fmr1
KO/App
KO
mice. For the behavioral testing, littermate controls were
generated by crossing Fmr1
KO/App
HET females with Fmr1
KO/
App
HET males to generate Fmr1
KO/App
WT, Fmr1
KO/App
HET and
Fmr1
KO/App
KO progeny and by crossing Fmr1
WT/App
HET females
with Fmr1
WT/App
HET males to generate Fmr1
WT/App
WT, Fmr1
WT/
App
HET and Fmr1
WT/App
KO progeny. Genotypes were determined
by PCR analysis of DNA extracted from tail biopsies. The WT,
HET or KO state of the App gene was determined by genotyping
with primer 1: 59-CTG CTG CAG GTG GCT CTG CA-39,
primer 2: 59-CAG CTC TAT ACA AGC AAA CAA G-39, and
primer 3: 59-CCA TTG CTC AGC GGT GCT GTC CAT-39 to
generate a 250 base pair WT allele with primers 1 and 2 and a 470
base pair targeted KO allele with primers 2 and 3.
Assessment of AbPP by Western Blot Analyses
Left hemispheres from WT, Fmr1
KO, App
HET and Fmr1
KO/
App
HET mice (1 month old males; n=3 per genotype) were
homogenized in protein extraction buffer [10 mM Tris (pH 7.6),
2 mM EDTA, 150 mM NaCl, 1% Triton X-100, 0.25% NP-40,
16 protease inhibitor cocktail (Research Products International
Corp., Mount Prospect, IL, USA, catalog #P50600)], mixed for
30 min at 4uC and spun at 12,000 rpm for 10 min at 4uC. The
protein concentrations of the supernatants were determined by
BCA assay (Thermo Fisher/Pierce, Rockford, IL, USA). Lysates
(18.75 mg per lane) were separated by 12% SDS-PAGE,
transferred to nitrocellulose and western blotted as previously
described [11] with anti-AbPP antibody (Life Technologies
Corporation, Carlsbad, CA, USA, catalog #51-2700; diluted
1:250) and anti-tubulin (Santa Cruz Biotechnology, Santa Cruz,
CA, catalog #sc-8035; diluted 1:250). AbPP signals were
normalized to tubulin and plotted as a percentage compared to
WT levels. Error bars represent the SEM of three mice.
Audiogenic Seizures
All mouse strains were tested at postnatal day 21, the peak of
AGS sensitivity in C57BL/6. The experimental apparatus
consisted of a clear, Plexiglas box (130L680W670H) with the
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TM jogger’s
alarm). Mice were weighed and then placed individually into the
center of the chamber and exposed to a siren that generated noise
at 118 dB for 5 min. Loud, acoustic stimulation causes WR within
20–30 sec followed by erratic leaping, clonic convulsions and tonic
hind limb extension by 40–50 sec followed by respiratory arrest
and death [32]. The percentage of mice exhibiting WR, AGS and
death were scored versus gender and genotype and assessed for
statistical significance by the Fisher exact test. The Fmr1
KO/App
HET
mice used in the AGS studies were offspring generated by crossing
Fmr1
KO females with Fmr1
KO/App
KO males to avoid effects due to
maternal genotype in comparing Fmr1
KO and Fmr1
KO/App
HET.
MPEP was a kind gift from FRAXA Research Foundation
(Newburyport, MA) and was dissolved at 1 mg/mL in DPBS
before I.P. injection at 30 mg/kg body weight 30 min prior to
AGS testing at age P21.
Marble Burying
Mice were acclimated to the behavioral testing room for at least
15 min prior to transfer to a clean cage containing corn cob
bedding and 20 black marbles arranged in a rectangular 465 grid
over 2/3 of the cage. The mouse was placed into the cage at the
end that did not contain marbles and allowed to explore the new
cage with the marbles for 30 min after which the mouse was
returned to its homecage and the number of visible marbles (more
than half not buried) counted. Background white noise in the room
was set to 70 dB. There is variability in this assay with some
laboratories observing that Fmr1
KO mice bury more marbles than
WT (R. Paylor, personal communication); however, differences in
behavioral outcomes can vary between facilities due to genetic
background or altered environmental factors such as housing
conditions and diet.
Open Field
Mice were acclimated to the behavioral testing room for at least
30 min before placement into the center of a clear, Plexiglas
chamber measuring 14.50L614.50W6100H. Mouse movement
was monitored in the chamber for 15 minutes with LimeLight2
software interfaced with an overhead camera. The open field
arena was arranged into a 16 square grid in the camera window
with 4 squares in the center and 12 squares around the perimeter.
Time spent in the center 4 squares (measure of anxiety) and total
distance traveled (measure of locomotion) were compared between
genotypes.
DiI Labeling and Analyses of Dendritic Spines
Primary mouse neurons were prepared from embryonic (age
E15–17) dissected brains from timed pregnant WT and Fmr1
KO
female mice as previously described) [11]. To generate Fmr1
KO/
App
HET cells, Fmr1
KO females were mated with Fmr1
KO/App
KO
males. Cells were cultured for 15 days on poly(D)-lysine coated
glass coverslips inside of 12-well tissue culture dishes, fixed with
4% paraformaldehyde and stained with lipophilic DiI dye (Life
Technologies Corporation, Carlsbad, CA, USA). For the staining,
the wells were aspirated and sprinkled with DiI crystals and a small
amount of DBPS was added to the edge of the wells to prevent
dehydration of the cells. Cells were stained for 10 min, copiously
washed with DPBS to remove all crystals and fixed to slides with
ProLong Gold Antifade (Life Technologies Corporation, Carls-
bad, CA, USA). Slides were allowed to dry for at least 3 days to
allow complete migration of the DiI into dendritic spines.
Dendritic spines were imaged on a Zeiss Axioplan 2 Imaging
Photomicroscope equipped with a MBF Biosciences automated
XYZ stage and MicroFire A/R camera. Images were taken using
the 1006 objective (Zeiss FLUAR 1006/1.30 oil) and Zeiss
Immersol
TM 518F oil at ambient temperature. Spine length was
quantitated with StereoInvestigator v9 software. Contours were
drawn around the protrusions and the feret max (length) and feret
min (widest width) of the contours were calculated. A minimum of
2–6 coverslips were analyzed per neuronal cell prep and images of
neurons were taken from multiple areas of those coverslips. Data is
representative of multiple batches of neuronal cells. A minimum of
746 spines were quantitated per genotype. The feret width was
divided by feret max and protrusions having a ratio less than 0.5
were classified as filopodia and those with a ratio greater than or
equal to 0.5 were classified as spines. For MPEP treatments,
2.5 mM MPEP was added to the neurons for the indicated times
followed by washing the cells with DPBS and fixation and staining
as previously described. A minimum of 263 protrusions were
quantitated per MPEP treatment.
Hippocampal Slice Preparation and mGluR-LTD Field
Recordings
WT, Fmr1
KO, App
HET and Fmr1
KO/App
HET mice were rapidly
decapitated by cervical dislocation (3-month old males). Hippo-
campal slices were prepared and electrophysiology performed as
previously described [88]. After a 50 min stable baseline, slices
were bathed in 50 mM S-DHPG for 10 min to induce mGluR-
LTD. A 2 min trace of an average of four 30 sec traces was
recorded over 100 min post-drug application and the slope of the
fEPSP was measured and graphed as a function of time.
Treatment, Staining and Immunofluorescence Analyses
of Primary Neurons
For inhibitor treatments, cells were pretreated with vehicle,
2.5 mM MPEP or 40 mM anisomycin for 15 min prior to culture
for 1 hr with vehicle or 20 nM Ab1–42.A b1–42 (CalBiochem,
catalog #171596) was prepared as previously described to
generate oligomers, but not high molecular weight or fibrillar
aggregates [89,90]. For antibody treatments, 10 mg mouse IgG
(Sigma #I5381) or anti-Ab (Santa Cruz, catalog #28365LS) were
added to 0.5 mL culture media inside transwells (Corning, catalog
#3460, 0.4 mm pore size) that were situated above neuron-coated
glass coverslips in 12-well tissue culture dishes. Each well
contained 1 mL culture media and the transwell contained an
additional 0.5 mL of culture media. Neurons were cultured for 3
days with the indicated antibodies prior to fixation and staining.
Cells were stained overnight with: anti-22C11 against the amino-
terminus of AbPP (Chemicon, catalog #MAB348, 1:2000), anti-
phosphERK (Santa Cruz, catalog #sc-23759, 1:100), anti-Arc/
Arg (Santa Cruz, catalog #sc-17839, 1:100), anti-Map1B (Santa
Cruz, catalog #58784, 1:100), anti-RhoB (Santa Cruz, catalog
#sc-180, 1:100) and anti-PSD95 (Santa Cruz, catalog #sc-71935,
1:100) followed by visualization with appropriate goat anti-mouse
or anti-rabbit rhodamine-conjugated secondary antibodies (Invi-
trogen, 1:500 for 30 min in the dark). Images were acquired with a
Nikon C1 Laser Scanning Microscope (Nikon Eclipse E600
upright microscope) using the 543 Diode (1 mw Mellet Griot)
laser, the Nikon Plan Apo 606/1.40 oil objective with Zeiss
Immersol
TM 518F oil at ambient temperature, and Nikon EZ-C1,
v3.91 software (Nikon Corp, Tokyo, Japan). Stained protein levels
in the puncta of 4–7 dendrites per sample were quantitated with
IMAGE J software using the Analyze Particles function (Rasband,
W.S., Image J, U.S. National Institutes of Health, Bethesda,
Maryland, USA, http://rsb.info.nih.gov/ij/, 1997–2006). Statis-
tical significance was determined by one-way ANOVA and
Student T-test analyses.
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Males with FXS and age-matched controls were recruited from
the FXS Clinic at Rush University Medical Center (RUMC) in
Chicago, IL. All FXS subjects (ages 9–32 years old) were positive
by DNA analyses for a fully methylated expansion mutation in the
FMR1 gene. Controls (age 23–33) were normal volunteers working
at RUMC and had no history of cognitive or mental health
disorders. The age and medications of the donors are listed in
Table S1. Blood was drawn from donors into lithium heparin-
coated blood collection tubes and spun at 1,500 rpm. The plasma
supernatant was removed and frozen at 280uC. The anti-
coagulated blood was mailed by overnight delivery from RUMC
to the University of Wisconsin-Madison where PBMC were
isolated within 24 hr.
Assessment of AbPP/AbPPa,A b1–40 and Ab1–42 by ELISA
Plasma was thawed and clarified at 12,000 rpm for 10 min at
4uC prior to ELISA assays for AbPP/AbPPa,A b1–40 and Ab1–42
per the manufacturer’s instructions (BioSource #KHB0051,
KHB3482, KHB3442) with the following modifications for the
Ab assays: (1) the sample volume was doubled from 50 mLt o
100 mL, (2) the incubation time was extended from 3 hr to
overnight at 4uC, and (3) after the overnight incubation, the
samples were removed from the antibody-coated wells prior to
addition of the detection antibody. PBMC were isolated as
previously described [91] and cultured for 24 hr prior to
harvesting the cells and culture media for ELISA analyses.
Hippocampus and neocortex (pre and post central gyri) samples
were sectioned from left cerebral hemispheres of control and FXS
brain autopsy tissue. Detergent-soluble lysates were prepared as
previously described) [11] for analyses of AbPP and Ab1–40.
Statistical Analyses
One-way ANOVA was performed using GraphPad Prism
version 5.0 d for Mac OS X (GraphPad Software, San Diego, CA)
to compare the means of three or more unmatched groups for the
behavioral and dendritic spine analyses. Student T-test analyses
were used to quantitate statistical significance for the western
blotting, marble burying, open field, dendritic spine protrusion
length, immunofluoresence and ELISA data. Fisher exact tests
were used to quantitate statistical significance for the AGS data.
Two-way ANOVA with Bonferroni posthoc tests was used to
quantitate statistical significance for the mGluR-LTD analyses.
Supporting Information
Figure S1 Assessment of hippocampal slice health.
Hippocampal slices from WT (black circles), Fmr1
KO (white
circles), App
HET (black triangles) and Fmr1
KO/App
HET (white
triangles) mice exhibit equivalent synaptic transmission as
determined by the input/output relationship (A) and ppf (B). i/o
was also measured at the end of the recordings to assess slice health
and showed similar i/o relationships to those shown in (A) (data
not shown). (B) fEPSP size as percent of first stimulus versus
interstimulus interval (msec). Data were analyzed by two-way
ANOVA/Bonferroni multiple comparison analyses. There were
no statistically significant differences in the i/o relationships. The
WT ppfs were statistically different (p,0.05) from App
HET (many
time points), WT versus Fmr1
KO (50 msec time point); WT versus
Fmr1
KO/App
HET (first four time points). There were no other
statistically significant differences in ppfs for the remaining
datasets.
(TIFF)
Figure S2 MPEP and Ab1–42 alter dendritic phosphoERK
levels. (A) WT and Fmr1
KO neurons were treated with 10 mM
MPEP [one-way ANOVA p,0.05, F=2.1], and (B) WT neurons
were treated with 20 nM Ab1–42 for the indicated times prior to
fixation and staining with anti-phosphoERK [one-way ANOVA
p,0.0001, F=13]. Stars (w) denote statistically different results by
Student T-test analyses (p,0.05).
(TIFF)
Table S1 Age and medications of donors.
(XLS)
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